What Is Lp-PLA2 (Lipoprotein-Associated Phospholipase A2)? Normal vs Optimal Range Explained

Lp-PLA2 fills a critical diagnostic gap that neither CRP nor standard lipid panels address—it measures inflammation happening specifically inside your arteries rather than generalized systemic inflammation from any source. The CTD maps over 380 compound interactions affecting Lp-PLA2 expression and the phospholipid oxidation pathways it catalyzes within atherosclerotic plaque. CRP can be elevated from a cold, obesity, autoimmune disease, or a stubbed toe—it is completely nonspecific. Lp-PLA2 is produced predominantly by macrophages that have infiltrated atherosclerotic plaque, hydrolyzing oxidized phospholipids on LDL particles to generate lysophosphatidylcholine and oxidized fatty acids—both of which amplify local vascular inflammation and destabilize the plaque. Values above 200 ng/mL indicate that this active plaque inflammation process is underway, even if CRP is normal. The most dangerous clinical scenario is elevated Lp-PLA2 with normal CRP, indicating localized vascular disease without the systemic inflammation that would trigger investigation.

The clinical evidence supporting Lp-PLA2 as an independent cardiovascular risk predictor is substantial. PubMed indexes over 4,800 publications on Lp-PLA2, with prospective cohort analyses from the ARIC, MESA, and Women's Health Study consistently demonstrating that elevated Lp-PLA2 predicts incident coronary heart disease, ischemic stroke, and cardiovascular death independently of standard risk factors including LDL cholesterol and CRP. The landmark meta-analysis by the Lp-PLA2 Studies Collaboration pooled data from over 79,000 participants across 32 studies, confirming a continuous graded relationship between Lp-PLA2 mass and cardiovascular events. The FDA cleared the PLAC test for Lp-PLA2 as an aid in assessing risk of coronary heart disease and ischemic stroke, making it one of the few inflammatory biomarkers with formal regulatory recognition for cardiovascular risk stratification.

Lp-PLA2 responds to interventions that stabilize arterial plaque. FAERS data document Lp-PLA2 changes across over 40 medication entries, with statins producing the most consistent reductions. Statins lower Lp-PLA2 by 20–35 percent through both direct anti-inflammatory effects on plaque macrophages and indirect reduction of oxidized LDL substrate that drives Lp-PLA2 production. The combination of Lp-PLA2 with ApoB and hs-CRP creates the most comprehensive cardiovascular risk assessment currently available: ApoB measures atherogenic particle burden, hs-CRP measures systemic inflammatory load, and Lp-PLA2 measures active plaque-specific inflammation. All three elevated simultaneously identifies the highest-risk individuals who benefit most from aggressive pharmacological and lifestyle intervention—and monitoring all three during treatment provides the most granular assessment of whether interventions are working at the arterial level.